tbuckley/cabot-search huggingface dataset:
Annals Consult Guys - Postoperative Delirium
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2021)

Web ExclusivesMarch 2021Annals Consult Guys - Postoperative DeliriumFREEGeno J. Merli, MD, Howard H. Weitz, MDGeno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this author, Howard H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this authorAuthor, Article and Disclosure Informationhttps://doi.org/10.7326/W20-0019 CME/MOC SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Annals Consult Guys discuss postoperative delirium—how to prevent it, diagnose it, and treat it—and call on Dr. Edward Marcantonio for expert advice.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article and Disclosure InformationDisclosures: Geno J. Merli, MD, and Howard H. Weitz, MD, report that they have no financial relationships or interests to disclose.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Stephanie Chang, MD, MPH, Deputy Editor, reports employment with the Agency for Healthcare Research and Quality, travel compensation from the Guidelines International Network, and participation in the Patient-Centered Outcomes Research Institute methodology committee. Vineet Chopra, MD, MSc, Deputy Editor, reports grants received from the Agency for Healthcare Research and Quality and royalties from UpToDate and Oxford University Press. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interests to disclose. Eliseo Guallar, MD, MPH, DrPH, Deputy Editor, Statistics, reports that he has no financial relationships or interests to disclose. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics March 2021Volume 174, Issue 3Page: CG1 ePublished: 16 March 2021 Issue Published: March 2021 CopyrightCopyright © 2021 by American College of Physicians. All Rights Reserved.Loading ...
P15.06 Safety of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody Plus Platinum/Etoposide in Untreated Extensive-Stage SCLC
Authors: L. Paz-Ares, M. Provencio, J.M. Trigo, S. Tannenbaum-Dvir, P. Basciano, D. Lathers, K. Urbanska, G. Kollia, C. He, A. Dipiero, A. Navarro
Journal: Journal of Thoracic Oncology (2021)
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
Authors: Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Robin K Avery, William A Werbel, Dorry L Segev, Jacqueline Garonzik-Wang, Julie J Paik
Journal: Annals of the Rheumatic Diseases (2021)

The safety of the SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal diseases (RMD) on immunomodulatory therapy is unknown because these individuals were largely excluded from the vaccine trials. The levels of systemic reactogenicity reported with SARS-CoV-2 mRNA vaccines to date have raised concern for a more serious adverse event profile in patients with underlying immune dysregulation. There is currently no direct evidence about mRNA vaccine safety in patients with RMD and current guidance is based on expert opinion.1 Concerns relating to the side effect profile of the SARS-CoV-2 mRNA vaccines have been identified as a primary concern of patients resulting in vaccine hesitancy.2 To assess tolerability and peri-vaccination reactogenicity in this patient population, we studied a sample of patients with RMD on immunomodulatory therapy who underwent early vaccination. 

Patients with RMD who received the SARS-COV-2 mRNA vaccine between 17 December 2020 and 11 February 2021 were recruited to participate in this observational cohort study by invitation on social media. Information on demographics, diagnoses and therapeutic regimens was collected. Participants completed an online questionnaire detailing any reactions experienced within the first week following the first vaccine dose.

We studied 325 participants with RMD, of whom 51% received Pfizer/BioNTech and 49% received Moderna vaccine. …
P37.34 Outcome Associations with p16, GATA-3, and TTF-1 Clone SP141 IHC Expression in Resected Stage I Lung Squamous Cell Carcinomas
Authors: A. Shevtsov, I. Yambayev, K. Suzuki, T. Sullivan, K. Rieger-Christ, E. Burks
Journal: Journal of Thoracic Oncology (2021)
SARS-CoV-2 Seroprevalence Data to Guide Local Public Health Interventions
Authors: Lao-Tzu Allan-Blitz, Jeffrey D. Klausner
Journal: JAMA Internal Medicine (2021)

Kristina L. Bajema, MD, MSc; Ryan E. Wiegand, MS; Kendra Cuffe, MPH; Sadhna V. Patel, MPH; Ronaldo Iachan, PhD; Travis Lim, DrPH; Adam Lee, MS; Davia Moyse, MA; Fiona P. Havers, MD, MHS; Lee Harding, MS; Alicia M. Fry, MD, MPH; Aron J. Hall, DVM, MSPH; Kelly Martin, MPH; Marjorie Biel, MPH; Yangyang Deng, MS; William A. Meyer III, PhD; Mohit Mathur, MD, PhD; Tonja Kyle, MS; Adi V. Gundlapalli, MD, PhD; Natalie J. Thornburg, PhD; Lyle R. Petersen, MD, MPH; Chris Edens, PhD
FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
Authors: J. Rotow, J. Patel, M. Hanley, H. Yu, J. Goldman, H. Nechustan, M. Scheffler, M. Awad, S. Clifford, A. Santucci, L. Silva, R. Tupper, G. Oxnard, J. Kherani, A. Drilon
Journal: Journal of Thoracic Oncology (2021)
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Authors: Lucille Stuani, Marie Sabatier, Estelle Saland, Guillaume Cognet, Nathalie Poupin, Claudie Bosc, Florence A. Castelli, Lara Gales, Evgenia Turtoi, Camille Montersino, Thomas Farge, Emeline Boet, Nicolas Broin, Clément Larrue, Natalia Baran, Madi Y. Cissé, Marc Conti, Sylvain Loric, Tony Kaoma, Alexis Hucteau, Aliki Zavoriti, Ambrine Sahal, Pierre-Luc Mouchel, Mathilde Gotanègre, Cédric Cassan, Laurent Fernando, Feng Wang, Mohsen Hosseini, Emeline Chu-Van, Laurent Le Cam, Martin Carroll, Mary A. Selak, Norbert Vey, Rémy Castellano, François Fenaille, Andrei Turtoi, Guillaume Cazals, Pierre Bories, Yves Gibon, Brandon Nicolay, Sébastien Ronseaux, Joseph R. Marszalek, Koichi Takahashi, Courtney D. DiNardo, Marina Konopleva, Véra Pancaldi, Yves Collette, Floriant Bellvert, Fabien Jourdan, Laetitia K. Linares, Christian Récher, Jean-Charles Portais, Jean-Emmanuel Sarry
Journal: The Journal of Experimental Medicine (2021)

Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias, and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell lines, PDXs, and patients with acute myeloid leukemia (AML) harboring an IDH mutation displayed an enhanced mitochondrial oxidative metabolism. Along with an increase in TCA cycle intermediates, this AML-specific metabolic behavior mechanistically occurred through the increase in electron transport chain complex I activity, mitochondrial respiration, and methylation-driven CEBPα-induced fatty acid β-oxidation of IDH1 mutant cells. While IDH1 mutant inhibitor reduced 2-HG oncometabolite and CEBPα methylation, it failed to reverse FAO and OxPHOS. These mitochondrial activities were maintained through the inhibition of Akt and enhanced activation of peroxisome proliferator-activated receptor-γ coactivator-1 PGC1α upon IDH1 mutant inhibitor. Accordingly, OxPHOS inhibitors improved anti-AML efficacy of IDH mutant inhibitors in vivo. This work provides a scientific rationale for combinatory mitochondrial-targeted therapies to treat IDH mutant AML patients, especially those unresponsive to or relapsing from IDH mutant inhibitors.
P78.06 Dynamic Risk Prediction for Disease Control With Nivolumab in Advanced or Recurrent Non-Small Cell Lung Cancer Patients (NewEpoch)
Authors: T. Fukui, S. Igawa, Y. Goto, K. Yoh, Y. Hosomi, T. Kato, K. Usui, K. Hirano, H. Tanaka, R. Saito, A. Bessho, H. Aono, A. Tamura, Y. Ohashi, M. Taguri, J. Sasaki, K. Naoki, H. Kunitoh
Journal: Journal of Thoracic Oncology (2021)
P14.19 CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1
Authors: M. Altan, R. Govindan, A. Schoenfeld, J. Noujaim, A. Sacher, J. Haanen, C. Huang, A. Hasan, T. Faitg, E. Butler, A. Shalabi, T. Owonikoko
Journal: Journal of Thoracic Oncology (2021)
PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
Authors: S. Novello, V. Monica, M. Serke, C. Grohe, A. Meyer, M. Geissler, I. Colantonio, E. Stoelben, F. Cecere, W. Schutte, C. Schumann, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, R. Chiari, V. Gregorc, M. Reck, C. Manegold, F. Griesinger, A. Follador, A. Ferrari, A. Bearz, O. Caffo, N. Dickgreber, L. Irtelli, G.h. Wiest, H. Sotoparra, M. Spatafora, L. Righi, V. Torri, L. Porcu, F. Arizio, G. Scagliotti
Journal: Journal of Thoracic Oncology (2021)
MA13.01 A Validation Study on DNA Repair Gene Variant for Lung Cancer Survival Prediction after Chemoradiation: A Secondary Analysis for RTOG-0617 Study
Authors: W. Wang, F.(. Kong, C. Hu, J. Jin, M. Machtay, J. Bogart, I.Y. Garces, S. Narayan, C.G. Robinson, V.S. Kavadi, J. Rothman, C.D. Koprowski, E. Gore, J. Welsh, R. Gaur, R.M. Macrae, G. Cannon, J. Bradley, B. Lu
Journal: Journal of Thoracic Oncology (2021)
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
Authors: Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, Erwin Tomasich, Katharina Feldmann, Teresa Hatziioannou, Stefan Traint, Wolfgang Lamm, Iris M Noebauer-Huhmann, Julia Furtner, Leonhard Müllauer, Gabriele Amann, Sebastian Bauer, Hans-Ulrich Schildhaus, Matthias Preusser, Gerwin Heller, Thomas Brodowicz
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Some sarcomas respond to immune checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA methylation profiles in relation to immunological parameters and response to anti-programmed cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients with sarcoma. Patients and methods We retrospectively identified adult patients who had received anti-PD-1 ICI therapy for recurrent sarcoma in two independent centers. We performed (1) blinded radiological response evaluation according to immune response evaluation criteria in solid tumors (iRECIST) ; (2) tumor DNA methylation profiling of &gt;850,000 probes using Infinium MethylationEPIC microarrays; (3) analysis of tumor-infiltrating immune cell subsets (CD3, CD8, CD45RO, FOXP3) and intratumoral expression of immune checkpoint molecules (PD-L1, PD-1, LAG-3) using immunohistochemistry; and (4) evaluation of blood-based systemic inflammation scores (neutrophil-to-lymphocyte ratio, leucocyte-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio). Response to anti-PD-1 ICI therapy was bioinformatically and statistically correlated with DNA methylation profiles and immunological data. Results 35 patients (median age of 50 (23–81) years; 18 females, 17 males; 27 soft tissue sarcomas; 8 osteosarcomas) were included in this study. The objective response rate to anti-PD-1 ICI therapy was 22.9% with complete responses in 3 out of 35 and partial responses in 5 out of 35 patients. Adjustment of DNA methylation data for tumor-infiltrating immune cells resulted in identification of methylation differences between responders and non-responders to anti-PD-1 ICI. 2453 differentially methylated CpG sites (DMPs; 2043 with decreased and 410 with increased methylation) were identified. Clustering of sarcoma samples based on these DMPs revealed two main clusters: methylation cluster 1 (MC1) consisted of 73% responders and methylation cluster 2 (MC2) contained only non-responders to anti-PD-1 ICI. Median progression-free survival from anti-PD-1 therapy start of MC1 and MC2 patients was 16.5 and 1.9 months, respectively (p=0.001). Median overall survival of these patients was 34.4 and 8.0 months, respectively (p=0.029). The most prominent DNA methylation differences were found in pathways implicated in Rap1 signaling, focal adhesion, adherens junction Phosphoinositide 3-kinase (PI3K)-Akt signaling and extracellular matrix (ECM)–receptor interaction. Conclusions Our data demonstrate that tumor DNA methylation profiles may serve as a predictive marker for response to anti-PD-1 ICI therapy in sarcoma.
Subcellular specificity of cannabinoid effects in striatonigral circuits
Authors: Edgar Soria-Gomez, Antonio C. Pagano Zottola, Yamuna Mariani, Tifany Desprez, Massimo Barresi, Itziar Bonilla-del Río, Carolina Muguruza, Morgane Le Bon-Jego, Francisca Julio-Kalajzić, Robyn Flynn, Geoffrey Terral, Ignacio Fernández-Moncada, Laurie M. Robin, José F. Oliveira da Cruz, Simone Corinti, Yasmine Ould Amer, Julia Goncalves, Marjorie Varilh, Astrid Cannich, Bastien Redon, Zhe Zhao, Thierry Lesté-Lasserre, Peggy Vincent, Tarson Tolentino-Cortes, Arnau Busquets-García, Nagore Puente, Jaideep S. Bains, Etienne Hebert-Chatelain, Gabriel Barreda-Gómez, Francis Chaouloff, Alexander W. Lohman, Luis F. Callado, Pedro Grandes, Jerome Baufreton, Giovanni Marsicano, Luigi Bellocchio
Journal: Neuron (2021)
Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study
Authors: Roberto Tonelli, Lara Pisani, Luca Tabbì, Vittoria Comellini, Irene Prediletto, Riccardo Fantini, Alessandro Marchioni, Dario Andrisani, Filippo Gozzi, Giulia Bruzzi, Linda Manicardi, Stefano Busani, Cristina Mussini, Ivana Castaniere, Ilaria Bassi, Marco Carpano, Federico Tagariello, Gabriele Corsi, Roberto d’Amico, Massimo Girardis, Stefano Nava, Enrico Clini
Journal: Pulmonology (2021)

This retrospective cohort study was conducted in two teaching hospitals over a 3-month period (March 2010-June 2020) comparing severe and critical COVID-19 patients admitted to Respiratory Intensive Care Unit for non-invasive respiratory support (NRS) and subjected to awake prone position (PP) with those receiving standard care (SC). Primary outcome was endotracheal intubation (ETI) rate. In-hospital mortality, time to ETI, tracheostomy, length of RICU and hospital stay served as secondary outcomes. Risk factors associated to ETI among PP patients were also investigated.A total of 114 patients were included, 76 in the SC and 38 in the PP group. Unadjusted Kaplan-Meier estimates showed greater effect of PP compared to SC on ETI rate (HR = 0.45 95% CI [0.2-0.9], p = 0.02) even after adjustment for baseline confounders (HR = 0.59 95% CI [0.3-0.94], p = 0.03). After stratification according to non-invasive respiratory support, PP showed greater significant benefit for those on High Flow Nasal Cannulae (HR = 0.34 95% CI [0.12-0.84], p = 0.04). Compared to SC, PP patients also showed a favorable difference in terms of days free from respiratory support, length of RICU and hospital stay while mortality and tracheostomy rate were not significantly different.Prone positioning in awake and spontaneously breathing Covid-19 patients is feasible and associated with a reduction of intubation rate, especially in those patients undergoing HFNC. Although our results are intriguing, further randomized controlled trials are needed to answer all the open questions remaining pending about the real efficacy of PP in this setting.
Abstract S03-02: Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study
Authors: Lewis Au, Annika Fendler, Laura Amanda Boos, Fiona Byrnes, Scott Shepherd, Emma Nicholson, Scaheen Kumar, Nadia Yousaf, Katalin Wilkinson, Anthony Swerdlow, Ruth Harvey, George Kassiotis, Robert Wilkinson, James Larkin, Samra Turajlic
Journal: Clinical Cancer Research (2021)

Abstract There is a pressing need to characterise the nature, extent and duration of immune response to SARS-CoV-2 in cancer patients, to inform risk-reduction strategies and preserve cancer outcomes. CAPTURE is a prospective, longitudinal cohort study of cancer patients and healthcare workers (HCWs) integrating immune profiles and clinical annotation. We evaluated 529 blood samples and 1051 oronasopharyngeal swabs from 144 cancer patients and 73 HCWs and correlated with &amp;gt;200 clinical variables. In patients with solid cancers and HCWs, S1-reactive and neutralising antibodies to SARS-CoV-2 were detectable five months post-infection. In these participants, SARS-CoV-2-specific T-cell responses were detected. CD4+ T-cell response correlated with S1 antibody levels. Patients with haematological malignancies had impaired but partially compensated immune responses, depending on malignancy and therapy. Overall, cancer stage, disease status, and therapies did not correlate with immune responses. These findings have implications for understanding individual risks and potential effectiveness of SARS-CoV-2 vaccination in this population. Citation Format: Lewis Au, Annika Fendler, Laura Amanda Boos, Fiona Byrnes, Scott Shepherd, Emma Nicholson, Scaheen Kumar, Nadia Yousaf, Katalin Wilkinson, Anthony Swerdlow, Ruth Harvey, George Kassiotis, Robert Wilkinson, James Larkin, Samra Turajlic. Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2021 Feb 3-5. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(6_Suppl):Abstract nr S03-02.
FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
Authors: F. Blanc-Durand, X. Mielgo Rubio, E. Auclin, S. Ponce-Aix, R. Lopez Castro, E. Nadal, D. Planchard, B. Routy, L. Hendriks, I. Sullivan, N. Dempsey, S. Pilotto, F. Aboubakar, D.J. Pinato, M. Castonguay, A. Rodriguez, A. Amores, M.V. Bluthgen, B. Duchemann, P. Cruz Castellano, C. Aguado De La Rosa, M. Sereno Moyano, J. Ruffinelli, G. Lopez, C. Caramella, B. Besse, L. Mezquita
Journal: Journal of Thoracic Oncology (2021)
Paul Schatzberger: GP, musician, and photographer
Authors: Abi Berger, Tom Schatzberger
Journal: BMJ (2021)

Portrait: Angela Rosenfeld

Paul Schatzberger couldn’t decide between medicine and music. But ultimately creativity ran through everything he did in life. He grew up in Manchester, the son of Jewish Viennese child refugees Rosl and Wolfgang. Paul’s love of music grew with violin lessons from the age of 6 and was further encouraged by his father, who taught him to play Viennese music on a piano accordion. Paul’s grandmother had been a concert pianist in Vienna before her life ended in Auschwitz.

In 1967, as he finished school, Paul was chosen by the Bridge of Britain Programme—a non-denominational, educational charity aimed at fostering “understanding between Britain and Israel, Jew and non-Jew, through practical educational and mainly social service exchange schemes.” He was selected because he was considered to be a significant young person who would be likely to make a difference in the world. He took his accordion and lived in a Kibbutz for six months.

At medical school his violin playing led him to become the leader of the …
P08.09 Optimal Follow Up Care for Patients with P-stage I Non-Small Cell Lung Cancer After Surgical Treatment
Authors: H. Notsuda, H. Oshio, R. Tanaka, Y. Watanabe, S. Eba, T. Suzuki, H. Oishi, A. Sakurada, Y. Okada
Journal: Journal of Thoracic Oncology (2021)
Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
Authors: Dina Schneider, Ying Xiong, Darong Wu, Peirong Hu, Leah Alabanza, Brittany Steimle, Hasan Mahmud, Kim Anthony-Gonda, Winfried Krueger, Zhongyu Zhu, Dimiter S. Dimitrov, Rimas J. Orentas, Boro Dropulić
Journal: Science Translational Medicine (2021)

Trispecific duoCAR-T cells with optimized costimulatory domains effectively kill tumor cells in antigen-heterogeneous and antigen-replete tumor models.
Association Between Hypertensive Disorders of Pregnancy and Neurodevelopmental Outcomes Among Offspring
Authors: Judith S. Brand, Deborah A. Lawlor, Henrik Larsson, Scott Montgomery
Journal: JAMA Pediatrics (2021)

Hypertensive disorders of pregnancy (HDP) have been associated with poorer neurodevelopmental outcomes in offspring, but the role of familial confounding in these associations is unclear.To investigate associations of maternal HDP with risks in offspring of autism spectrum disorders (ASDs), attention-deficit/hyperactivity disorder (ADHD), and intellectual disability (ID), as well as variation in overall cognitive performance in offspring.This Swedish register-based study used data from a birth cohort divided into 1 085 024 individuals born between 1987 and 1996 and followed up until December 31, 2014, and 285 901 men born between 1982 and 1992 who attended assessments for military conscription, including a cognitive function test. Statistical analysis was performed from April 1, 2019, to June 1, 2020.Diagnoses of HDP, which were provided by the Medical Birth Register.Diagnoses of ASDs, ADHD, and ID were extracted from the National Patient Register. Cognitive function was assessed using written tests and summarized as a single 9-point score. Whole-cohort and within-sibship analyses were performed; the latter accounted for unmeasured familial confounding factors shared by siblings.The study included 1 085 024 individuals (556 912 male participants [51.3%]) born between 1987 and 1996 and 285 901 men born between 1982 and 1992 who attended assessments for military conscription. The prevalence of maternal HDP was 4.0% in the 1987-1996 birth cohort (n = 42 980) and 5.1% in the military conscription cohort (n = 14 515). A total of 15 858 participants received a diagnosis of ASD, 36 852 received a diagnosis of ADHD, and 8454 received a diagnosis of ID. The mean (SD) cognitive score among the men in the conscription cohort was 5.1 (1.9). In whole-cohort analyses with multivariable adjustment, HDP were associated with offspring ASDs (hazard ratio [HR], 1.22; 95% CI, 1.13-1.31), ADHD (HR, 1.10; 95% CI, 1.05-1.16), and ID (HR, 1.39; 95% CI, 1.27-1.53). Analyses comparing siblings discordant for HDP were less statistically powered but indicated estimates of similar magnitude for ASDs (HR, 1.19; 95% CI, 1.00-1.42) and possibly ADHD (HR, 1.09; 95% CI, 0.95-1.24), but not for ID (HR, 1.04; 95% CI, 0.83-1.29). Hypertensive disorders of pregnancy were associated with somewhat lower cognitive scores in whole-cohort analysis (mean difference comparing offspring exposed with those unexposed, -0.10; 95% CI, -0.13 to -0.07), but in within-sibship analysis, the association was null (mean difference, 0.00; 95% CI, -0.09 to 0.08).The study results suggest that HDP are associated with small increased risks of ASDs and possibly ADHD in offspring, whereas associations with ID and cognitive performance are likely confounded by shared familial (environmental or genetic) factors.
P84.14 Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling.
Authors: E. Sánchez-Herrero, R. Serna-Blasco, V. Ivanchuk, R. Garcia Campelo, M. Dómine Gómez, J.M. Sanchez, B. Massuti, N. Reguart, C. Camps, S. Sanz-Moreno, S. Fariñas, E. Jantus-Lewintre, M. Arnal, D. Fernández-Orth, V. González-Rumayor, V. Calvo, M. Provencio, A. Romero
Journal: Journal of Thoracic Oncology (2021)
Incessant型上室性頻拍を呈したlong RP頻拍の1例-房室結節リエントリーと心房内リエントリーとの鑑別
Authors: 大道近也, 柿澤祥子, 石下晃子, 山田綾子, 石井康宏, 長嶋浩貴, 田中健, 上松瀬勝男, 遠藤真弘, 鈴木文男
Journal: Circulation (2007)